<p>Kestra Medical Technologies (KMTS) 最近引起了投资者的关注，交易后股价约为 22.23 美元，过去一周、一个月和三个月的回报表现各异。</p>
<p>请查看我们对 Kestra Medical Technologies 的最新分析。</p>
<p>最近一个月股价回报为 14.23%，与年初至今的 8.86% 较弱的股价表现和 1 年总股东回报 11.50% 形成对比。这表明短期动能有所增强，而长期回报仍然承压。</p>
<p>如果这种反弹引起了你的注意，可能是使用我们的筛选器查看 32 只医疗保健 AI 股票的好时机。</p>
<p>Kestra Medical Technologies 的交易价格约为 22.23 美元，距离某些分析师的目标价大约低 25%，关键问题是这是否反映了低估，还是当前价格已经包含了未来的增长潜力。</p>
<h2>最受欢迎的叙述：低估 24%</h2>
<p>Kestra Medical Technologies 最近收盘价为 22.23 美元，而叙述的公允价值约为 29.14 美元，目前的设置集中在远超今天损失的增长预期上。</p>
<blockquote>
<p><em>美国市场的类别渗透率仅为 14%，目前只有 14% 的合格患者使用可穿戴除颤器，这为采用创造了广阔的空间，支持持续的两位数处方增长和加速的收入扩张。</em></p>
</blockquote>
<p><em>阅读完整叙述。</em></p>
<p>想知道需要什么样的收入增长和利润率变化才能支撑这个公允价值吗？这个叙述依赖于激进的收入增长和未来盈利能力的预期，这与今天的情况截然不同。关键的变动因素很明确，但增长、规模和定价能力的确切组合尚不清楚。</p>
<p>在这个最受关注的叙述核心中，假设相对较小的收入基础 8370 万美元可以迅速复合，而每年净亏损 1.481 亿美元会随着时间的推移而缩小。估值工作是基于 7.7% 的折现率，收入增长、未来收益和溢价收益倍数都为每股约 29.14 美元的公允价值提供了支持。</p>
<p><strong>结果：公允价值为 29.14 美元（低估）</strong></p>
<p>完整阅读叙述，了解预测背后的内容。</p>
<p>然而，这取决于更广泛的可穿戴除颤器采用和更强的支付方合同；停滞的指南或较弱的报销可能会迅速削弱这个 24% 的低估故事。</p>
<p>了解这个 Kestra Medical Technologies 叙述的关键风险。</p>
<h2>另一种观点：价格看起来被高估</h2>
<p>这个 24% 的低估公允价值与当前的市销率 15.5 倍显得格格不入，远高于美国医疗设备行业的 3 倍、同行的 2.2 倍，甚至公允比率的 3.9 倍。如果增长令人失望，还有多少空间在情绪转变之前？</p>
<p>查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f234930c-1894-4e82-8da8-ea90a6b70471/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA0LTI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="650" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f234930c-1894-4e82-8da8-ea90a6b70471/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA0LTI4"/></p>
<p>截至 2026 年 4 月的 NasdaqGS:KMTS 市销率</p>
<h2>下一步</h2>
<p>在这个故事中看到乐观和担忧，自己查看数字是有意义的，快速决定你的位置，然后权衡 1 个关键回报和 1 个重要警告信号。</p>
<h2>寻找更多投资想法？</h2>
<p>如果 Kestra 引起了你的兴趣，不要止步于此。通过其他专注的股票想法来扩展你的观察名单，这些股票可能适合你投资组合中的不同角色。</p>
<ul>
<li>通过扫描相对优质的低估公司，寻找潜在的错误定价机会，使用我们的 53 只高质量低估股票。</li>
<li>通过审查提供稳定分红的企业，增强你的收入来源，查看 13 只分红堡垒。</li>
<li>通过检查在稳定性和财务韧性方面得分良好的公司，优先考虑资本保护，查看 73 只低风险股票。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3>估值复杂，但我们在这里简化它。</h3>
<p>通过我们的详细分析，发现 Kestra Medical Technologies 是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、分红、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

KMTS

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>Kestra Medical Technologies (KMTS) 的股票目前价格为 22.23 美元，过去一个月回报率为 14.23%，但年初至今仅为 8.86%。分析师建议的公允价值为 29.14 美元，显示出潜在的 24% 低估。该公司面临的挑战是其市销率高达 15.5 倍，远高于行业平均水平，这引发了对未来增长的担忧。可穿戴除颤器的采用对收入增长至关重要，但风险包括指导方针停滞和报销问题。建议投资者评估估值，并考虑更广泛的投资机会</p>

<p>Kestra Medical Technologies (KMTS) has drawn investor attention after recent trading left the shares around $22.23, with a mixed return profile across the past week, month and past 3 months.</p>
<div class="lb-trans"><p>Kestra Medical Technologies (KMTS) 最近引起了投资者的关注，交易后股价约为 22.23 美元，过去一周、一个月和三个月的回报表现各异。</p>
</div><p>See our latest analysis for Kestra Medical Technologies.</p>
<div class="lb-trans"><p>请查看我们对 Kestra Medical Technologies 的最新分析。</p>
</div><p>The recent 14.23% 1 month share price return contrasts with weaker year to date share price performance of 8.86% and a 1 year total shareholder return of 11.50%. This suggests short term momentum has picked up while longer term returns remain under pressure.</p>
<div class="lb-trans"><p>最近一个月股价回报为 14.23%，与年初至今的 8.86% 较弱的股价表现和 1 年总股东回报 11.50% 形成对比。这表明短期动能有所增强，而长期回报仍然承压。</p>
</div><p>If this kind of rebound has your attention, it may be a good moment to look across the sector using our screener for 32 healthcare AI stocks</p>
<div class="lb-trans"><p>如果这种反弹引起了你的注意，可能是使用我们的筛选器查看 32 只医疗保健 AI 股票的好时机。</p>
</div><p>With Kestra Medical Technologies trading around $22.23 and sitting roughly 25% below one set of analyst price targets, the key question is whether this reflects undervaluation or whether the current price already captures future growth potential.</p>
<div class="lb-trans"><p>Kestra Medical Technologies 的交易价格约为 22.23 美元，距离某些分析师的目标价大约低 25%，关键问题是这是否反映了低估，还是当前价格已经包含了未来的增长潜力。</p>
</div><h2>Most Popular Narrative: 24% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：低估 24%</h2>
</div><p>With Kestra Medical Technologies last closing at $22.23 versus a narrative fair value of about $29.14, the current setup centers on growth expectations that stretch well beyond today’s losses.</p>
<div class="lb-trans"><p>Kestra Medical Technologies 最近收盘价为 22.23 美元，而叙述的公允价值约为 29.14 美元，目前的设置集中在远超今天损失的增长预期上。</p>
</div><blockquote>
<p><em>Category underpenetration in the U.S. with only 14% of eligible patients currently using a wearable defibrillator creates a long runway for adoption, supporting sustained double digit prescription growth and accelerating revenue expansion.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>美国市场的类别渗透率仅为 14%，目前只有 14% 的合格患者使用可穿戴除颤器，这为采用创造了广阔的空间，支持持续的两位数处方增长和加速的收入扩张。</em></p>
</blockquote>
</div><p><em>Read the complete narrative.</em></p>
<div class="lb-trans"><p><em>阅读完整叙述。</em></p>
</div><p>Curious what kind of revenue ramp and margin shift need to sit behind that fair value? The narrative leans on aggressive top line gains and a future profitability profile that looks very different to today. The key moving parts are clear, but the exact mix of growth, scale and pricing power is not.</p>
<div class="lb-trans"><p>想知道需要什么样的收入增长和利润率变化才能支撑这个公允价值吗？这个叙述依赖于激进的收入增长和未来盈利能力的预期，这与今天的情况截然不同。关键的变动因素很明确，但增长、规模和定价能力的确切组合尚不清楚。</p>
</div><p>At the core of this most followed narrative is the assumption that a relatively small revenue base of $83.7 million can compound rapidly, while annual net losses of $148.1 million narrow over time. The valuation work is built using a discount rate of 7.7%, with revenue growth, future earnings and a premium earnings multiple all feeding into a fair value of roughly $29.14 per share.</p>
<div class="lb-trans"><p>在这个最受关注的叙述核心中，假设相对较小的收入基础 8370 万美元可以迅速复合，而每年净亏损 1.481 亿美元会随着时间的推移而缩小。估值工作是基于 7.7% 的折现率，收入增长、未来收益和溢价收益倍数都为每股约 29.14 美元的公允价值提供了支持。</p>
</div><p><strong>Result: Fair Value of $29.14 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 29.14 美元（低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的内容。</p>
</div><p>However, this hinges on wider wearable defibrillator adoption and stronger payer contracts; stalled guidelines or weaker reimbursement could quickly undermine that 24% undervalued story.</p>
<div class="lb-trans"><p>然而，这取决于更广泛的可穿戴除颤器采用和更强的支付方合同；停滞的指南或较弱的报销可能会迅速削弱这个 24% 的低估故事。</p>
</div><p>Find out about the key risks to this Kestra Medical Technologies narrative.</p>
<div class="lb-trans"><p>了解这个 Kestra Medical Technologies 叙述的关键风险。</p>
</div><h2>Another View: Price Tag Looks Stretched</h2>
<div class="lb-trans"><h2>另一种观点：价格看起来被高估</h2>
</div><p>That 24% undervalued fair value sits awkwardly next to the current P/S of 15.5x, which is far above the US Medical Equipment industry at 3x, peers at 2.2x and even the fair ratio of 3.9x. If growth disappoints, how much room is there before sentiment flips?</p>
<div class="lb-trans"><p>这个 24% 的低估公允价值与当前的市销率 15.5 倍显得格格不入，远高于美国医疗设备行业的 3 倍、同行的 2.2 倍，甚至公允比率的 3.9 倍。如果增长令人失望，还有多少空间在情绪转变之前？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f234930c-1894-4e82-8da8-ea90a6b70471/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA0LTI4" alt="" original-src="https://images.simplywall.st/company/f234930c-1894-4e82-8da8-ea90a6b70471/chart/ps-multiple-vs-industry?date=2026-04-28"/></p>
<p>NasdaqGS:KMTS P/S Ratio as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 NasdaqGS:KMTS 市销率</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>Seeing both optimism and concern in this story, it makes sense to look at the numbers yourself, decide quickly where you stand before sentiment shifts, and then weigh up the 1 key reward and 1 important warning sign</p>
<div class="lb-trans"><p>在这个故事中看到乐观和担忧，自己查看数字是有意义的，快速决定你的位置，然后权衡 1 个关键回报和 1 个重要警告信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If Kestra has sparked your interest, do not stop here. Broaden your watchlist with other focused stock ideas that could suit different roles in your portfolio.</p>
<div class="lb-trans"><p>如果 Kestra 引起了你的兴趣，不要止步于此。通过其他专注的股票想法来扩展你的观察名单，这些股票可能适合你投资组合中的不同角色。</p>
</div><ul>
<li>Target potential mispriced opportunities by scanning companies that look cheap relative to quality using our 53 high quality undervalued stocks.</li>
<li>Strengthen your income stream by reviewing businesses that offer resilient payouts through the 13 dividend fortresses.</li>
<li>Prioritize capital protection by checking companies that score well on stability and financial resilience via the 73 resilient stocks with low risk scores.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描相对优质的低估公司，寻找潜在的错误定价机会，使用我们的 53 只高质量低估股票。</li>
<li>通过审查提供稳定分红的企业，增强你的收入来源，查看 13 只分红堡垒。</li>
<li>通过检查在稳定性和财务韧性方面得分良好的公司，优先考虑资本保护，查看 73 只低风险股票。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里简化它。</h3>
</div><p>Discover if Kestra Medical Technologies might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Kestra Medical Technologies 是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、分红、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

评估 Kestra Medical Technologies (KMTS) 在近期股价上涨后的估值